Shutting down cancer with Gleevec, Brian Druker
Interviewee: Brian Druker. Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments. (DNAi Location: Applications > Genes and medicine > Drug design > Brian Druker > Shutting down cancer)
If you look back at the history of cancer research, in many respects for 30 or 40 years we've been stumbling around in the dark. We understood that cancer is probably a genetic disease but what those genetic abnormalities are that caused the uncontrolled growth of cancer in most cases remain elusive. With Gleevec we've shown that if you understand what drives the growth of a cancer you can shut it down specifically.
chronic myeloid leukemia,causes of cancer,gleevec,location applications,genetic abnormalities,dnai,cancer research,uncontrolled growth,genetic disease,cml,interviewee,leukemia,brian druker,genes,respects,medicine
- ID: 15082
- Source: DNALC.DNAi
- Download: Theora Video MPEG 4 Video
15057. Before and after Gleevec, Brian Druker
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
15055. Using DNA science to control CML, Brian Druker
Brian Druker talks about how the drug he designed targets the molecular cause of CML.
15054. Restoring hope with Gleevec, Brian Druker
Brian Druker talks about how Gleevec has restored patients' hope for the future.
15525. How Gleevec works to alleviate symptoms of myeloid leukemia, 3D animation with basic narration
View the animation to find out how the drug Gleevecâ¢ inhibits the molecular cause of chronic myeloid leukemia.
15056. Approval for Gleevec in record time, Brian Druker
Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.
15042. The first day of clinical trials for Gleevec, Bud and Yvonne
Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.
15041. Getting the diagnosis of chronic myeloid leukemia, Bud
Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.
1013. Diagnosis, Targeted therapies: Targeting activators, Sawyer 1
Professor Charles Sawyer explains that CML stands for chronic myeloid leukemia, which is a blood cancer and it is different from many cancers because it starts very slowly and patients when they're first diagnosed don't have many symptoms.
15706. Philadelphia chromosome
A mutation that gives rise to the Philadelphia chromosome gives rise to leukemia.
15994. The chronic myeloid leukemia (CML) mutation
View the animation to learn about the Philadelphia chromosome, the abnormal chromosome that causes chronic myeloid leukemia.